Alpha Fowler III The Use of Intravenous Vitamin C in Sepsis Part 1

Alpha Fowler III, MD helped define the cellular and molecular inflammatory events that evolve in the pulmonary microvascular and pulmonary alveolar space as humans develop acute lung injury. During his faculty years at Virginia Commonwealth University, his laboratory has been active modeling acute lung injury, carefully defining the molecular phenomena that produce injury while at the same time focusing on interventional therapies to attenuate acute lung injury following the onset of bacterial sepsis. His laboratory has expertise in understanding and modeling cellular and molecular mechanisms that produce acute lung injury. He continues to be involved in clinical critical care medicine as an attending physician where he cares for many patients with acute lung injury. He and his colleagues at academic medical centers recently completed an NIH-funded randomized, double blind, placebo-controlled phase II trial the examined the extent to which high dose intravenous vitamin C attenuates multiple organ failure and lung injury following onset of sepsis.